3 citations,
January 2021 in “Plastic and Aesthetic Research”
Hair loss reduces hair thickness and coverage, but drug treatments mainly revive dormanthairs rather than reverse thinning; patients often undervalue their hair loss severity.
1 citations,
January 2015 in “Journal of Aesthetic & Reconstructive Surgery”
Hair transplantation is the best treatment for hair loss, with new technologies improving results, and stem cell and gene therapies may treat severe baldness in the future.
Finasteride and minoxidil can revive hairdormant for up to 7 years, with microneedling enhancing regrowth. Users report significant hair regrowth even after long periods of baldness.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
PP405 is not a cure for hair loss but may reactivate dormanthair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormanthair follicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hair follicles, improving hair thickness and quality.
PP405 is a promising molecule that may reactivate dormanthair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.